Antipsychotic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Schizophrenia, Bipolar Disorder, Unipolar Disorder, Dementia, Others), By Drug Classification (First Generation (Typical), Second Generation (Atypical)), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 15.78 Billion
CAGR (2026-2031)	8.91%
Fastest Growing Segment	Schizophrenia
Largest Market	North America
Market Size (2031)	USD 26.33 Billion

Market Overview

The Global Antipsychotic Drugs Market is projected to grow from USD 15.78 Billion in 2025 to USD 26.33 Billion by 2031 at a 8.91% CAGR. Antipsychotic drugs are a class of psychiatric medication primarily administered to manage psychosis, including delusions, hallucinations, and disordered thinking associated with schizophrenia, bipolar disorder, and severe depression. The market is fundamentally supported by the rising prevalence of mental health conditions globally, alongside improved diagnostic capabilities and government initiatives aimed at destigmatizing psychiatric care. These factors collectively necessitate a sustained demand for effective therapeutic interventions. According to the World Health Organization, in 2025, more than 1 billion people worldwide were living with a mental disorder. This substantial patient pool underpins the consistent requirement for long-term pharmacological management strategies.

However, a significant challenge impeding market expansion is the prevalence of severe adverse effects associated with antipsychotic pharmacotherapy, such as metabolic syndrome, weight gain, and tardive dyskinesia. These complications frequently result in poor patient adherence and high discontinuation rates, thereby limiting the realized commercial potential of existing treatment regimens and creating barriers to consistent revenue generation.

Key Market Drivers

The escalating global prevalence of schizophrenia and bipolar disorders constitutes the primary catalyst propelling the market. These chronic, debilitating conditions require lifelong pharmacological management, thereby securing a steady demand for antipsychotic therapeutics. As diagnostic criteria improve and healthcare systems in emerging economies expand, the identified patient population requiring treatment continues to widen, directly translating into increased prescription volumes. According to the World Health Organization, October 2025, in the 'Schizophrenia' fact sheet, this disorder affected approximately 23 million people worldwide, highlighting the critical need for accessible therapeutic options. This consistent expansion of the patient pool underpins the sector's financial resilience. According to Otsuka Holdings, in 2025, the company's pharmaceutical segment revenue increased by 17.1% during the fiscal year 2024, driven largely by sustained global demand for its psychiatric medication portfolio.

Simultaneously, the accelerated adoption of Long-Acting Injectable (LAI) formulations is reshaping the market landscape by addressing the pervasive issue of patient non-adherence. By reducing the dosing frequency from daily oral intake to monthly or bi-monthly injections, LAIs significantly improve therapeutic outcomes and reduce relapse rates, encouraging clinicians to prioritize these formulations over traditional treatments. This clinical shift lowers discontinuation rates and fosters higher patient compliance, thereby ensuring consistent revenue streams for pharmaceutical manufacturers. According to Alkermes plc, February 2025, in the 'Alkermes plc Reports Financial Results for Q4 and Full Year 2024', revenues for its proprietary LAI product ARISTADA grew 16% year-over-year to $96.6 million in the fourth quarter, illustrating the substantial commercial viability of this advanced delivery mechanism.

Download Free Sample Report

Key Market Challenges

The prevalence of severe adverse effects associated with antipsychotic pharmacotherapy constitutes a critical barrier to the expansion of the Global Antipsychotic Drugs Market. Side effects such as metabolic syndrome, weight gain, and tardive dyskinesia significantly diminish the tolerability of these medications, forcing many patients to discontinue treatment prematurely. When patients experience debilitating physical complications alongside their psychiatric condition, their willingness to sustain long-term pharmacological regimens declines sharply. This interruption in therapy directly undermines the recurring revenue streams that pharmaceutical manufacturers rely upon, as the realization of commercial potential depends heavily on consistent, uninterrupted usage over a patient’s lifetime.

The economic impact of this non-adherence is profound and directly hampers market value. High discontinuation rates reduce the total volume of drug consumption, thereby stagnating sales figures despite the rising global prevalence of mental disorders. According to the National Community Pharmacists Association, in 2025, up to 50% of patients with chronic conditions failed to take their medications as prescribed. This substantial rate of non-compliance, driven largely by tolerability issues, restricts the market's ability to fully capitalize on the diagnosable patient pool, effectively capping revenue generation and stalling overall industry advancement.

Key Market Trends

The emergence of antipsychotics with novel non-dopaminergic mechanisms represents a significant market evolution, addressing the critical need for effective treatments with improved tolerability profiles. Unlike traditional agents that primarily block dopamine D2 receptors, leading to metabolic syndrome and motor side effects, this new class targets systems such as muscarinic acetylcholine receptors to modulate psychotic symptoms. This shift is attracting substantial investment as manufacturers seek to capture the market share of patients who discontinue standard therapies due to adverse events. According to Bristol Myers Squibb, March 2024, the company solidified its leadership in this high-value segment by completing the acquisition of Karuna Therapeutics for a total equity value of $14 billion, highlighting the industry's massive financial commitment to these first-in-class non-dopaminergic therapies.

Simultaneously, the expansion of indications for adjunctive treatment of Major Depressive Disorder (MDD) is broadening the commercial horizon for third-generation atypical antipsychotics. As monotherapy antidepressants frequently fail to achieve remission in complex cases, clinicians are increasingly prescribing these agents as add-on therapies, effectively unlocking a patient population far larger than that of schizophrenia alone. This strategic label expansion enables pharmaceutical companies to maximize the lifecycle value of their assets and sustain growth despite patent pressures in other portfolios. According to AbbVie, April 2024, in the 'First-Quarter 2024 Financial Results', global net revenues for its flagship psychiatric drug Vraylar increased by 23.6% to $694 million, a surge driven largely by its growing adoption in the management of mood disorders including adjunctive MDD.

Segmental Insights

The Schizophrenia segment is anticipated to witness the fastest growth in the Global Antipsychotic Drugs Market, primarily driven by the rising prevalence of severe mental disorders as highlighted by the World Health Organization. This growth is further supported by the introduction of new therapeutic options and increasing approvals from regulatory bodies like the US FDA, particularly for long-acting injectable formulations that improve medication adherence. The escalating need for consistent long-term management of this chronic condition ensures a sustained demand for medication, thereby positioning the Schizophrenia segment as a primary contributor to overall market development.

Regional Insights

North America maintains a leading position in the global antipsychotic drugs market primarily due to the high prevalence of mental health conditions such as schizophrenia and bipolar disorder. The region benefits from a strong presence of major pharmaceutical companies that invest heavily in research and development. Additionally, favorable regulatory initiatives by the U.S. Food and Drug Administration streamline product approvals, ensuring steady market growth. Comprehensive healthcare reimbursement structures further support patient access to medication, consolidating North America as the primary revenue generator in this sector.

Recent Developments

• In December 2024, Reviva Pharmaceuticals announced positive preliminary topline data from the long-term open-label extension of its Phase 3 RECOVER study for brilaroxazine in the treatment of schizophrenia. The study results demonstrated that the novel serotonin-dopamine signaling modulator maintained a favorable safety and tolerability profile along with robust efficacy over a one-year duration. Patients treated with the drug showed sustained improvements in all major symptom domains, supporting its potential as a long-term maintenance therapy. The company indicated that these findings would form a critical component of its upcoming New Drug Application submission to regulatory authorities.
• In September 2024, Bristol Myers Squibb announced the U.S. FDA approval of Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in adults. This event represented a major breakthrough in the antipsychotic drugs market, introducing the first new class of medicine for schizophrenia in decades that does not directly block dopamine receptors. The approval was based on the EMERGENT clinical program, where the drug showed statistically significant reductions in symptom severity compared to placebo. The Chief Executive Officer of Bristol Myers Squibb noted that this novel muscarinic agonist approach offers a differentiated treatment option for patients who have historically relied on dopaminergic therapies.
• In August 2024, AbbVie completed its strategic acquisition of Cerevel Therapeutics, a clinical-stage biopharmaceutical company specializing in neuroscience. The transaction, valued at approximately $8.7 billion, integrated Cerevel’s portfolio into AbbVie’s pipeline, adding complementary assets for psychiatric and neurological conditions. A primary focus of the acquisition was emraclidine, a potential best-in-class antipsychotic with a novel mechanism of action targeting the muscarinic M4 receptor for the treatment of schizophrenia. The company stated that this move would strengthen its neuroscience foundation and drive sustainable long-term performance by delivering new therapies for disorders with significant unmet medical needs.
• In April 2024, Vanda Pharmaceuticals received U.S. FDA approval for Fanapt (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. This regulatory milestone significantly expanded the commercial potential of the atypical antipsychotic, which was previously utilized primarily for schizophrenia. The approval was supported by data from a Phase III clinical study involving approximately 400 patients, where the drug demonstrated a statistically significant improvement in mania symptoms compared to placebo. The company highlighted that this development offers a flexible dosing option with a known safety profile for patients suffering from bipolar I disorder.

Key Market Players

• Eli Lily and Company
• AstraZeneca plc
• GlaxoSmithKline plc
• Johnson & Johnson
• Otsuka Pharmaceutical Co, Ltd.
• Pfizer Inc.
• AbbVie Inc.
• Dr. Reddy’s Laboratories Limited
• Otsuka Holdings Co., Ltd.
• Teva Pharmaceutical Industries Ltd

By Application	By Drug Classification	By Region
Schizophrenia Bipolar Disorder Unipolar Disorder Dementia Others	First Generation (Typical) Second Generation (Atypical)	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Antipsychotic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Antipsychotic Drugs Market, By Application:

• Schizophrenia
• Bipolar Disorder
• Unipolar Disorder
• Dementia
• Others

• Antipsychotic Drugs Market, By Drug Classification:

• First Generation (Typical)
• Second Generation (Atypical)

• Antipsychotic Drugs Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE